

ASX Announcement

Date of AGM & Closing Date for Director Nominations

Perth, Australia; 10 September 2026: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) advises, in accordance with ASX Listing Rule 3.13.1, that the 2026 Annual General Meeting (“AGM”) of the Company will be held on Friday, 6 November 2026.

An item of business at the AGM will be the re-election of Directors. The Company advises that, in accordance with clause 6.1 of the Company’s Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a Director is Friday, 18 September 2026.

Any nominations must be received at the Company’s registered office no later than 5.00 pm WST on Friday, 18 September 2026.

Release authorised by:
Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited
CEO and MD
P: +61 8 9360 2888
E: paul.anderson@orthocell.com

Media enquiries

Haley Chartres
HACK Director
P: +61 423 139 163
E: haley@hackhq.com.au

Investor enquiries

Shaun Duffy
VECTOR Advisors
P: +61 404 094 384
E: sduffy@vectoradvisors.au



About Orthocell Limited

ACN 118 897 135

Registered Office – Level 2, 161 Campus Drive, Murdoch University, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd